- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Alumis Inc.: Alumis to Participate in Upcoming September Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 14.08. | Alumis reports Q2 results | 1 | Seeking Alpha | ||
| 13.08. | ALUMIS INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.08. | ALUMIS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | Alumis Inc.: Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements | 73 | GlobeNewswire (Europe) | - Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis - - Initiated Phase 1 clinical trial for A-005 in healthy participants - - Completed IPO... ► Artikel lesen | |
| 29.07. | Alumis Inc.: Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis | 89 | GlobeNewswire (Europe) | - Co-primary endpoint of PASI 75 and sPGA 0/1 score at 24 weeks to serve as basis for U.S. regulatory submission - - Pivotal Phase 3 program supported by positive Phase 2 STRIDE clinical data as well... ► Artikel lesen | |
| 24.07. | Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation | 1 | Benzinga.com | ||
| 18.07. | ALUMIS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.07. | Alumis resumes decline a day after first positive session post IPO | 1 | Reuters | ||
| 01.07. | ALUMIS INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 01.07. | ALUMIS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.07. | Alumis dips day after listless Nasdaq debut | 1 | Reuters | ||
| 28.06. | Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering | 1 | Benzinga.com | ||
| 28.06. | Alumis, in trading debut, falls 22% from IPO price | 1 | Seeking Alpha | ||
| 28.06. | Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut | 1 | Reuters | ||
| 28.06. | Alumis Opens At $13.50, IPO Priced At $16 | 1 | Investing.com | ||
| 28.06. | Inflammation Biotech Alumis Trims IPO Plans But Still Raises $250M for Clinical Trials | 1 | MedCity News | ||
| 28.06. | Alumis raises $250m in IPO as biotech stock stirs | 1 | Pharmaceutical Technology | ||
| 28.06. | Alumis cuts IPO size, but nets $250M for immune drug work | 1 | BioPharma Dive | ||
| 28.06. | Immunology biotech Alumis prices downsized IPO at $16, the low end of the range | 2 | Renaissance Capital |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,955 | -0,73 % | Qiagen will neue Wandelanleihen ausgeben | Qiagen kündigt die Emission von Wandelanleihen an. Die Emission soll ein Gesamtvolumen von bis zu 450 Millionen Dollar haben, so das Unternehmen am Dienstag. Die Anleihe wird in einer Stückelung von... ► Artikel lesen | |
| EVOTEC | 5,940 | -2,14 % | Evotec, HelloFresh, nucera, TUI, Vonovia - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| DYNE THERAPEUTICS | 33,040 | -1,81 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
| NUVALENT | 86,25 | +1,52 % | Nuvalent stock retains Overweight rating as Barclays focuses on Phase 1 ROS1 data at ESMO | ||
| BIONTECH | 81,45 | +0,37 % | Bayer, Vidac Pharma, BioNTech - Healthcare Sektor vor einer Renaissance | In den letzten Monaten zeigen sich verheißungsvolle Anzeichen für eine Renaissance des Healthcare-Sektors. Innovative Start-ups treiben trotz Investitionsrückgängen die digitale Transformation voran... ► Artikel lesen | |
| IMMUNOVANT | 34,030 | +1,22 % | Immunovant Inc.: Immunovant to Host Graves' Disease Program Update on September 9, 2024 | ||
| TARSUS PHARMACEUTICALS | 30,650 | +12,23 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements | Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,250 | -3,04 % | Adma biologics executive trades shares worth over $400,000 | ||
| BAVARIAN NORDIC | 31,410 | -0,25 % | AKTIONÄR-Depotwert Bavarian Nordic: UNICEF mit Paukenschlag | Die Ausbreitung von Mpox in Afrika bereitet Experten weiterhin Sorgen. Um das Problem in den Griff zu bekommen, hat das UN-Kinderhilfswerk UNICEF in mehreren Ländern eine Notfallausschreibung für Mpox-Impfstoff... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 12,290 | -1,68 % | Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024 | MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,915 | -4,13 % | Recursion Pharmaceuticals, Inc.: Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability | REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment... ► Artikel lesen | |
| CG ONCOLOGY | 38,020 | +1,22 % | CG Oncology director sells over $23 million in company stock | ||
| BB BIOTECH | 39,100 | -2,62 % | BB Biotech: Vom neuen Sektor-Aufschwung profitieren | Die Anzeichen einer neuen Biotech-Hausse verdichten sich. Immer mehr Profis positionieren sich für eine längerfristige Sektor-Rallye. Cleveres Stockpicking ist jetzt entscheidend. Alternativ setzen... ► Artikel lesen | |
| ARCELLX | 71,20 | +1,18 % | Arcellx CMO sells over $239k in company stock | ||
| JANUX THERAPEUTICS | 41,330 | -5,44 % | Navigating 5 Analyst Ratings For Janux Therapeutics |
Das Unternehmen ALUMIS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,93 % bei einem Aktienkurs von 11,920 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALUMIS INC finden Sie auf Wallstreet Online.
